Testing suggests TORC1 inhibitors can boost immune system in the elderly

July 12, 2018 by Bob Yirka, Medical Xpress report
TORC1 contributes to aging in all species. Credit: resTORbio

A team of researchers affiliated with Novartis Institutes for Biomedical Research and Biometrics Matters Limited, has found via testing with volunteers that TORC1 inhibitors can boost the immune system in the elderly. In their paper published in the journal Science Translational Medicine, the group describes the study they conducted and the results they found.

Most people know that as we get older our immune systems become less robust—we hear warnings every year of the risk that influenza poses for those over age 65. Because a weaker immune system can lead to possibly preventable deaths, scientists have been looking for ways to either prevent immune system weakening or to bolster it in older people. In this new effort, the researchers suggest they might have found a way to achieve the latter.

Prior research has shown that a protein complex called TORC1 is involved in immune response—it has also been tied to immune system decline in older people. In this new effort, the researchers sought to learn more about it by carrying out a phase 2a clinical trial on the use of two TORC1 inhibitors— RAD001 and BEZ235, in . Both drugs are already in common use to treat other ailments, which meant that the team did not have to test them for safety first.

Volunteers in the study included 264 healthy people over the age of 65. Some were given RAD001, others BEZ235, and another group received both. Some were also used as a control group. The volunteers were given doses of their designated drugs for a period of six weeks, and all of them were monitored for a year. Over that time span, every incidence of illness or infection was recorded for all of the volunteers.

Respiratory tract infections represent a significant health risk to the elderly. Credit: resTORbio

The researchers report that those volunteers who had received both drugs had the lowest infection rates—1.49 per person. In contrast, those who received a placebo had an infection rate of 2.41. This, the researchers suggest, indicates that the drugs did boost the immune system. As further proof, they noted that some of the volunteers received flu shots not long after being given the drugs. Testing of those volunteers thereafter showed that they had more influenza antibodies in their bloodstreams indicating the immune system was putting up a healthier fight against the threat of .

Explore further: Early-stage respiratory syncytial virus (RSV) vaccine trial begins

More information: Joan B. Mannick et al. TORC1 inhibition enhances immune function and reduces infections in the elderly, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aaq1564

Abstract
Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation. In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce infections in the elderly.

Related Stories

Early-stage respiratory syncytial virus (RSV) vaccine trial begins

June 14, 2018
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched a clinical trial of an investigational vaccine designed to protect against respiratory syncytial ...

Phase I HIV vaccine trial to begin

March 28, 2018
A Phase I clinical trial testing the safety of vaccines that might have the potential to prevent HIV infection will begin this month at four sites in the United States, marking the latest step in a three-decade quest at UMass ...

H7N9 influenza vaccine clinical trials begin

March 15, 2018
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies, sponsored by the National ...

Prime-boost H7N9 influenza vaccine concept promising in clinical trial

December 10, 2015
In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential ...

Double-blind study suggests humans have olfactory defense against contagious disease

May 24, 2017
(Medical Xpress)—A European team of researchers working at Sweden's Karolinska Institutet has found evidence that suggests that humans have an olfactory defense against contagious diseases. In their paper published in Proceedings ...

Recommended for you

A gut bacterium as a fountain of youth? Well, let's start with reversing insulin resistance

November 16, 2018
Move over Bifidobacterium and Lactobacillus. There's a new health-promoting gut bacterium in town, and it's called Akkermansia muciniphila.

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Pets can double as asthma antidote

November 16, 2018
(HealthDay)—The "hygiene hypothesis" holds that early exposure to a variety of microorganisms may decrease the risk for chronic inflammatory diseases, like asthma.

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Defense against intestinal infection in organism is affected by prostaglandin E2

November 15, 2018
The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.

No link between 'hypoallergenic' dogs and lower risk of childhood asthma

November 15, 2018
Growing up with dogs is linked to a lower risk of asthma, especially if the dogs are female, a new study from Karolinska Institutet and Uppsala University in Sweden shows. However, the researchers found no relation between ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.